glp-1 obesity drug news october 21 2025 Americans Need More Information About Weight Loss Drugs 2024 was a record year

Description

Tirzepatide has received approval for use in patients with T2D following several phase 3 studies testing and demonstrating its marked anti-hyperglycemic efficacy and positive actions on multiple cardiovascular risk factors, associated with an excellent safety profile [2, 3]

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society

These changes explain the range of gastrointestinal symptoms patients experience, from diarrhea to constipation

Lancet Neurol 14(3):329340 Biessels GJ, Verhagen C, Janssen J et al (2019) Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial